Physician profile
David Dipietro
NPI 1689659922
$3,713.12
in general payments reported to CMS, 2019-2025
29 companies · $869 in 2025
The $869 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $562 · 2021: $534 · 2022: $366 · 2023: $452 · 2024: $552 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $639.48 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $563.65 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $523.43 | 2021-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $349.05 | 2019-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $244.99 | 2019-2025 | |
| Bausch Health US, LLC | $220.43 | 2019-2025 | Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $208.61 | 2019-2023 | Austedo, Austedo Xr |
| Exact Sciences Corporation | $122.14 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $111.32 | 2020-2024 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $71.40 | 2024-2025 | Gemtesa |
| Boston Scientific Corporation | $67.29 | 2022-2025 | Bodyguardian |
| Astellas Pharma US INC | $64.64 | 2024 | Veozah |
| Regeneron Healthcare Solutions, INC. | $56.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.99 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $45.72 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $43.91 | 2023-2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $41.22 | 2020-2021 | |
| Abbvie INC. | $39.68 | 2021 | |
| Amarin Pharma, INC. | $38.82 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $33.42 | 2023 | Rexulti |
| Lundbeck LLC | $31.63 | 2022-2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $22.53 | 2021 | |
| Medicomp INC | $22.31 | 2025 | Telepatch Cardiac Monitor |
| Daiichi Sankyo INC. | $19.40 | 2024 | Injectafer |
| Seqirus USA INC | $18.16 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Phathom Pharmaceuticals, INC. | $18.12 | 2024 | Voquezna |
| Vertos Medical, INC. | $17.06 | 2020 | |
| Eisai INC. | $16.74 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dipietro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.